DATESBIO

Overview

Updated: Sep 4, 2026

Company Overview

Oncolytic Virus and Mesenchymal Stem Cell Complex-Based Cancer Therapeutics

Address

Headquarters :2nd Floor, Administrative Building, Yonsei Medical Center 50-1, Yonsei-ro, Seodaemungu, Seoul, South Korea

Research Center :-

Website

http://datesbio.com/html/

Class

Pharmaceutical

Partnering Goals

Private

Investment Info

Investment History

Total USD 360K

2022.07
360K
Investor Amount
Evergreen Investment Partners 360K

Investor	Amount
Evergreen Investment Partners	360K

Shareholders

Jaejin Song

Severancebiopharma

Evergreen Investment Partners

HeekyoungKim principal researcher

Funding Goal

Target StageSeries A

Target Amount1.5 - 3.8M

Funding Purpose

Goal 1.5M ~ 3.8M Use of Funds - Demonstrate superiority over competitive standard treatments - Establish production and purification processes - GMP manufacturing

Team

Key People

CEO

Jaejin Song

Ph.D. in Natural Sciences, Yonsei University Professor, Yonsei University Lead Researcher, IlYang Pharmaceutical

Director

Rhyum, Sun-Boon

Master's in Microbiology, Chungnam National University Director, BioPS Co., Ltd.

Principal researcher

Heekyoung Kim

Ph.D. in Pharmacy, Deokseong Women's University Yale Univ. research scientist

Advisors

Private

Tech & Products

Technology Details

Complex composed of independent modules (oncolytic virus, mesenchymal stem cell)

- Expansion from rheumatoid arthritis therapeutics to autoimmune and further to chronic inflammation-related diseases - Positive efficacy results in in vivo rheumatoid arthritis models are directly linked to the optimization of oncolytic virus tumor-targeting; the eMSC technology is fully dedicated as a viral missile drug delivery platform, signifying the completion of the OV/MSC approach

Comparing with conventional single MSC

When compared with conventional single MSC injection, the amount of MSCs reaching the target is more than 100-fold higher, and the fundamental therapeutic capacity is enhanced through pain relief and cartilage regeneration, enabling competitiveness against existing DMARDs such as methotrexate, TNF-α inhibitors, and JAK inhibitors.

Problem & Unmet Needs

Private

Market Trends

Oncology Market

The global oncology market is projected to reach USD 268 billion by 2026, while the global cell and gene therapy market is expected to continue steady growth, reaching USD 12 billion by 2025.

CAR-T cell therapy

For CAR-T cell therapy, the most competitive emerging technology in cell and gene therapy, the domestic (Korean) market is forecasted to grow from USD 13 million in 2021 to USD 346 million in 2030 (CAGR 33.8%). The global market is expected to expand from USD 1.3 billion in 2021 to USD 17.3 billion in 2030.

Pancreatic Cancer

The global pancreatic cancer diagnosis and treatment market is projected to grow from USD 1.73 billion in 2015 to USD 2.3 billion by 2026. By 2025, the global autoimmune disease therapeutics market is expected to reach USD 153 billion, comparable in size to oncology, the largest disease market.

Rheumatoid Arthritis Therapeutics Market

The global rheumatoid arthritis therapeutics market, valued at approximately USD 36 billion in 2022, is projected to grow at a CAGR of 4.72%, reaching USD 52 billion by 2030. However, there is still significant unmet need, as no drug currently offers a complete cure for rheumatoid arthritis.

Competitive Landscape

Key Differentiators

Cell therapy shows low target delivery, yet IV administration enables distal therapeutic effect

Pipeline

DBM-011

Indication

Musculoskeletal

Modality

Cells

Sub-Modality

Stem Cells

Current Stage

Preclinical

In vitroIn vivoPreclinical

Pipeline

DBM-012

Indication

Immunology

Modality

Cells

Sub-Modality

Stem Cells

Current Stage

In vivo

In vitroIn vivoPreclinical

Pipeline

DBM-013

Indication

Gastroenterology

Modality

Cells

Sub-Modality

Stem Cells

Current Stage

Private

In vitroIn vivoPreclinical

Pipeline

DBM-014

Indication

Respiratory

Modality

Cells

Sub-Modality

Stem Cells

Current Stage

Private

In vitroIn vivoPreclinical

Pipeline

DBM-101

Indication

Oncology

Modality

Cells

Sub-Modality

Stem Cells

Current Stage

Preclinical

In vitroIn vivoPreclinical

Pipeline

DBM-102

Indication

Oncology

Modality

Cells

Sub-Modality

Stem Cells

Current Stage

Preclinical

In vitroIn vivoPreclinical

Pipeline

DBM-104

Indication

Oncology

Modality

Cells

Sub-Modality

Stem Cells

Current Stage

Preclinical

In vitroIn vivoPreclinical

Patents & Papers

Papers

Private

Patents

Patent Title

Mesenchymal stem cells capable of enhancing tumor targeting and enabling largescale oncolytic virus production

Status

Filed

Application Year

Private

Application Countries

KR/JP/AU/US/EP/CN/CA/RU

Patent Title

Mesenchymal stem cells capable of enhancing tumor targeting and enabling largescale oncolytic virus production

Status

Filed

Application Year

Private

Application Countries

KR

Latest News

Private

Overview

Company Overview

DATESBIO

Investment Info

Investment History

Shareholders

Funding Goal

Team

Key People

Advisors

Tech & Products

Development of biopharmaceuticals based on eMSC as a DDS platform – Innovation, Differentiation, ExpDifferentiated Technology - lung first-pass + active systemic targeting : Unsecured globally eMSC - High-level common modularized active pharmaceutical ingredients (APIs)

Development of biopharmaceuticals based on eMSC as a DDS platform – Innovation, Differentiation, Exp

Technology Details

Complex composed of independent modules (oncolytic virus, mesenchymal stem cell)

Comparing with conventional single MSC

Problem & Unmet Needs

Market Trends

Oncology Market

CAR-T cell therapy

Pancreatic Cancer

Rheumatoid Arthritis Therapeutics Market

Competitive Landscape

Key Differentiators

Pipeline

Patents & Papers

Papers

Patents

Latest News